Metformin as a Metabolic Intervention in Oesophageal Adenocarcinomas to Improve Response to Neoadjuvant Chemoradiotherapy

NCT06687876 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

14

Enrollment

OTHER

Sponsor class

Conditions

Oesophageal Adenocarcinoma
Tumor Microenvironment

Interventions

DRUG: Metformin

Sponsor

Amsterdam UMC, location VUmc

Collaborators

[object Object]